Corporate strategy

MerLion Pharmaceuticals explores collaboration opportunities with interested parties to:

  • commercialize XtoroTM in the USA and Canada, where it has already been approved for market,
  • achieve market authorization and commercialization of XtoroTM  in other regions of the world, including Europe,
  • develop finafloxacin against biothreat pathogens and, subsequently, commercialize finafloxacin in this field,
  • complete the clinical development and begin with the commercialization of finafloxacin for the treatment of patients suffering from complicated urinary tract infections (cUTIs) and pyelonephritis, as well as further serious infections that require hospitalization.

For business development and partnering inquries, please contact: